For the year ending 2025-12-31, CUE made $27,466K in revenue. -$26,602K in net income. Net profit margin of -96.85%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 27,466 | 9,287 | ||
| General and administrative | 16,244 | 14,585 | ||
| Research and development | 37,743 | 36,295 | ||
| Loss (gain) on fixed asset disposal | -31 | 93 | ||
| Total operating expenses | 54,018 | 50,787 | ||
| Loss from operations | -26,552 | -41,500 | ||
| Interest income | 807 | 1,622 | ||
| Interest expense | -357 | -796 | ||
| Total other income, net | 450 | 826 | ||
| Loss before provision for income taxes | 26,102 | - | ||
| Provision for income taxes | 500 | - | ||
| Net loss | -26,602 | -40,674 | ||
| Comprehensive loss | - | -40,674 | ||
| Basic EPS | -0.28 | -0.72 | ||
| Diluted EPS | -0.28 | -0.72 | ||
| Basic Average Shares | 94,731,768 | 56,328,348 | ||
| Diluted Average Shares | 94,731,768 | 56,328,348 | ||
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)